France Oncology Drugs Market Analysis Report 2022 to 2030

France Oncology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the France oncology drugs market will reach a value of $12.1 Bn from $5.4 Bn in 2022, growing at a CAGR of 10.6% during 2022-2030. The oncology drug market in France is dominated by a few large pharmaceutical companies such as Sanofi, Novartis, Roche, and Pfizer. The oncology market in France is segmented into different therapeutic areas, such as breast cancer, lung cancer, colorectal cancer, prostate cancer, and others. The market is also segmented based on treatment types, such as surgery, radiation therapy, chemotherapy, and targeted therapy.

ID: IN10FRPH018 CATEGORY: Pharmaceuticals GEOGRAPHY: France AUTHOR: Dr. Vishwa Modhia

Buy Now

France Oncology Drugs Market Analysis Summary

By 2030, it is anticipated that the France oncology drugs market will reach a value of $12.1 Bn from $5.4 Bn in 2022, growing at a CAGR of 10.6% during 2022-30. In France, breast oncology was connected to the highest expenditure (2.1% of total expenditures) among the four specific oncology sites (lung, colorectal, and prostate).

In France in 2019, about 12% of total health spending went toward oncology care. In 2020, France was expected to have a 340 per 100,000 population age-standardized incidence rate of oncology. Comparatively speaking to other European nations, France has a higher cumulative risk of incidence, at 32.7%. As compared to other places, this one has a lower mortality risk of 11.2%. This is attributable to a competent healthcare system that the general public can access and rely on.

france oncology drugs market

Market Dynamics

Market Growth Drivers Analysis

Strong spending trends in the French oncology market were notable; these trends were frequently linked to extremely expensive therapeutic innovations. This is demonstrated by the sharp rise in drug and device costs outside of the diagnosis-related group in 2017 for the treatment of lung oncology, which most likely came about as a result of the introduction of particular immunotherapies (nivolumab and pembrolizumab).

Market Restraints

The high cost involved in research and development in oncological drugs and high out-of-pocket expenditure can refrain new players to enter the market in France.

Competitive Landscape

Key Players

Pierre Fabre (FRA)
Sanofi (FRA)
Xenothera (FRA)
Zionexa (FRA)
Roche
Celgene
AstraZeneca Plc
Bristol-Myers Squibb

Notable Recent Deals

January 2023: Servier and Aqemia announce an extension of their joint new-molecule discovery project focused on an immuno-oncology therapeutic target that is intractable. This extension continues the productive partnership between Servier and Aqemia that was started in December 2021 to use artificial intelligence to speed up the discovery of drug candidates in the field of immuno-oncology.

December 2022: Innate Pharma SA and Sanofi announced an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKETTM (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKETTM targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing, and commercialization.

Reimbursement

A cardinal metric system that reflects the added value of the product is used in France to determine the maximum reimbursement level and price for new medications. Each pharmaceutical product is given two ratings: one that reflects the product's actual medical benefit (SMR - Service Médical Rendu), which establishes the level of reimbursement, and another that assesses whether the medical benefit has improved (ASMR - Amélioration du service médical rendu), which determines whether a price premium can be achieved or whether a discount will be necessary.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Drugs Market Segmentation

By Drug class

Cytotoxic drugs
- Alkylating agents
- Antimetabolites
- Others
Targeted drugs
- Monoclonal antibodies
- Others
Hormonal drugs
Others

By Therapy

Chemotherapy
Targeted therapy
Immunotherapy

By Indication

Lung cancer
Stomach cancer
Colorectal cancer
Breast cancer
Prostate cancer
Others

By Dosage form

Solid
- Tablets
- Capsules
Liquid
Injectable
- Prefilled syringes
- Others

By Distribution channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
?Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.